Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19074055 | POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDES | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19048328 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | February 2025 | December 2025 | Abandon | 10 | 1 | 0 | No | No |
| 19048080 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | February 2025 | January 2026 | Abandon | 11 | 2 | 0 | No | No |
| 18965675 | NOVEL CRISPR ENZYMES AND SYSTEMS | December 2024 | January 2026 | Allow | 14 | 2 | 1 | Yes | No |
| 18926774 | PHYLLOBACTERIUM MYRSINACEARUM STRAIN N1N2-2 FOR EFFICIENT DEGRADATION OF DIPHENYLARSINIC ACID AND USE THEREOF | October 2024 | May 2025 | Allow | 6 | 2 | 1 | No | No |
| 18847017 | SIALYLTRANSFERASES FOR THE PRODUCTION OF SIALYLATED OLIGOSACCHARIDES | September 2024 | February 2025 | Allow | 5 | 0 | 0 | Yes | No |
| 18666610 | Mannanase Variants and Polynucleotides Encoding Same | May 2024 | March 2026 | Allow | 22 | 3 | 1 | Yes | No |
| 18693613 | METHOD FOR THE FERMENTATIVE PRODUCTION OF L-LYSINE USING C. GLUTAMICUM STRAINS EXPRESSING MODIFIED GLUCONATE REPRESSOR PROTEINS GNTR1 AND GNTR2 | March 2024 | December 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18601266 | METHODS OF MAKING CHITOSAN | March 2024 | September 2025 | Allow | 18 | 0 | 0 | Yes | No |
| 18416306 | POLYMERASE ENZYME FROM PHAGE T4 | January 2024 | April 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18515603 | ENGINEERED POLYMERASES FOR IMPROVED SEQUENCING BY BINDING | November 2023 | August 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18513744 | TARDIGRADE DISORDERED PROTEINS AS PROTEIN STABILIZERS | November 2023 | February 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18476753 | NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | September 2023 | March 2025 | Allow | 18 | 1 | 1 | Yes | No |
| 18471901 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | September 2023 | June 2025 | Allow | 20 | 1 | 0 | Yes | No |
| 18471524 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | September 2023 | March 2025 | Allow | 17 | 1 | 1 | Yes | No |
| 18464514 | DETERGENT COMPOSITIONS AND USES THEREOF | September 2023 | April 2025 | Abandon | 19 | 2 | 1 | No | No |
| 18462921 | NON-TOXIC CAS9 ENZYME AND APPLICATION THEREOF | September 2023 | September 2024 | Abandon | 12 | 1 | 1 | No | No |
| 18455969 | GERANYLGERANYL PYROPHOSPHATE SYNTHASES | August 2023 | June 2025 | Abandon | 22 | 2 | 1 | Yes | No |
| 18454556 | METHOD FOR PRODUCING ETHANOL FROM LIGNOCELLULOSIC RAW MATERIAL | August 2023 | November 2025 | Allow | 53 | 3 | 0 | Yes | No |
| 18348277 | Methods of Treating Fabric Using a Streptococcus Hexosaminidase | July 2023 | May 2024 | Allow | 10 | 0 | 1 | Yes | No |
| 18346420 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | July 2023 | December 2023 | Allow | 5 | 1 | 0 | Yes | No |
| 18320389 | IN VITRO TRANSCRIPTION/TRANSLATION (TXTL) SYSTEM AND USE THEREOF | May 2023 | July 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18314979 | Platform for developing stable mammalian cell lines | May 2023 | November 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 18313195 | METHOD FOR INCREASING YIELD OF 7-DEHYDROCHOLESTEROL IN YEAST BY USING COMPARTMENTALIZATION | May 2023 | November 2025 | Abandon | 30 | 4 | 1 | No | No |
| 18299479 | REDUCED GENOME E. COLI LACKING TOXIN-ANTITOXIN GENES | April 2023 | March 2024 | Allow | 11 | 1 | 1 | No | No |
| 18127674 | METHOD FOR PREPARING AN ANTIMYCIN COMPOUND PRODUCED BY STREPTOMYCES SP.4-7 | March 2023 | October 2023 | Allow | 7 | 1 | 0 | No | No |
| 18183191 | L-GLUTAMATE DEHYDROGENASE MUTANT AND APPLICATION THEREOF | March 2023 | May 2024 | Abandon | 14 | 0 | 1 | No | No |
| 18044250 | ESTERASE AND METHODS OF USE, THEREOF | March 2023 | March 2026 | Allow | 36 | 1 | 1 | Yes | No |
| 18172517 | METHOD FOR TREATING A TISSUE DEFECT WITH A COLLAGEN-CONTAINING MEMBRANE | February 2023 | November 2024 | Allow | 21 | 1 | 0 | No | No |
| 18159745 | PROCESSES AND SYSTEMS FOR CATALYTIC MANUFACTURE OF WAX ESTER DERIVATIVES | January 2023 | January 2024 | Allow | 11 | 2 | 0 | Yes | No |
| 18159735 | PROCESSES AND SYSTEMS FOR CATALYTIC MANUFACTURE OF WAX ESTER DERIVATIVES | January 2023 | August 2024 | Allow | 18 | 3 | 0 | No | No |
| 18157512 | ENGINEERED GLUCOSYLTRANSFERASES | January 2023 | August 2024 | Allow | 19 | 1 | 1 | No | No |
| 18084888 | NOVEL NADH-DEPENDENT ENZYME MUTANTS TO CONVERT ACETONE INTO ISOPROPANOL | December 2022 | February 2024 | Allow | 14 | 1 | 0 | Yes | No |
| 18061840 | CONVERSION OF LIGNIN INTO BIOPLASTICS AND LIPID FUELS | December 2022 | December 2024 | Allow | 25 | 1 | 1 | Yes | No |
| 18057800 | METHODS OF RECOMBINANTLY PRODUCING NEUTRAL PROTEASE ORIGINATING FROM PAENIBACILLUS POLYMXA | November 2022 | October 2024 | Allow | 23 | 1 | 1 | No | No |
| 18057854 | TETHERING CYSTEINE RESIDUES USING CYCLIC DISULFIDES | November 2022 | January 2025 | Abandon | 26 | 2 | 1 | No | No |
| 18053614 | Polypeptides | November 2022 | July 2024 | Allow | 20 | 0 | 0 | Yes | No |
| 17972132 | Minimal Peptide Fusions for Targeted Intracellular Degradation of FOXP3 | October 2022 | March 2025 | Abandon | 29 | 2 | 1 | No | No |
| 17996202 | RECOMBINANT FUSION PROTEIN FOR PREVENTING OR TREATING FIBROTIC DISEASES | October 2022 | January 2026 | Abandon | 39 | 0 | 1 | No | No |
| 18045573 | DETERGENT COMPOSITIONS AND USES THEREOF | October 2022 | April 2024 | Abandon | 18 | 1 | 1 | Yes | No |
| 17916652 | THERMOSTABLE PHYTASE FOR LOW SODIUM STARCH LIQUEFACTION | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17913678 | BIOFILM ENHANCED TEXTILE AND METHODS FOR MANUFACTURING THEREOF | September 2022 | January 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17931214 | De novo designed rotor (axle:ring) protein assemblies | September 2022 | February 2026 | Abandon | 41 | 0 | 1 | No | No |
| 17930761 | POLYNUCLEOTIDES ENCODING APOA1-RNASE FUSION POLYPEPTIDES | September 2022 | December 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17941373 | GENETICALLY ENGINEERED VIBRIO SP. AND USES THEREOF | September 2022 | March 2025 | Allow | 30 | 3 | 1 | Yes | No |
| 17930203 | Polypeptides having Xylanase Activity and Polynucleotides Encoding Same | September 2022 | September 2024 | Allow | 24 | 5 | 0 | No | No |
| 17801644 | SYNTHESIS OF C-GLYCOSIDES OF INTEREST | August 2022 | July 2025 | Abandon | 34 | 0 | 1 | No | No |
| 17820155 | CNS DELIVERY OF THERAPEUTIC AGENTS | August 2022 | May 2025 | Allow | 33 | 3 | 1 | No | No |
| 17887538 | STRAIN OF PSEUDOMONAS AERUGINOSA 9# AND APPLICATIONS THEREOF | August 2022 | August 2024 | Abandon | 24 | 2 | 0 | No | No |
| 17799016 | MANNANASE VARIANTS | August 2022 | September 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17798973 | MANNANASE VARIANTS | August 2022 | October 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17796500 | MANNANASE VARIANTS AND POLYNUCLEOTIDES ENCODING SAME | July 2022 | September 2025 | Allow | 38 | 2 | 1 | Yes | No |
| 17814371 | HUMAN ALPHA-GALACTOSIDASE VARIANTS | July 2022 | May 2024 | Allow | 21 | 2 | 1 | No | No |
| 17791566 | METHOD FOR PREPARING SOY LEGHEMOGLOBIN USING ESCHERICHIA COLI | July 2022 | December 2025 | Abandon | 41 | 0 | 1 | No | No |
| 17757734 | METHOD OF PURIFYING BOTUFINUM TOXIN | June 2022 | May 2025 | Allow | 35 | 1 | 1 | Yes | No |
| 17751200 | TRANSAMINASE REACTIONS | May 2022 | October 2024 | Allow | 29 | 3 | 1 | No | No |
| 17749857 | METHOD FOR PRODUCING USEFUL SUBSTANCE | May 2022 | December 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17745205 | BETA-LACTAMASE VARIANTS | May 2022 | March 2024 | Abandon | 22 | 2 | 0 | No | No |
| 17739028 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | May 2022 | June 2023 | Allow | 14 | 1 | 1 | Yes | No |
| 17772820 | STRAIN WITH IMPROVED AROMATIC AMINO ACID PRODUCTION CAPACITY BY ANSB GENE INACTIVATION | April 2022 | February 2024 | Abandon | 22 | 1 | 1 | No | No |
| 17728812 | FLUORESCENCE-BASED REPORTERS FOR MUTAGENESIS DETECTION IN E. COLI | April 2022 | August 2023 | Allow | 15 | 2 | 1 | Yes | No |
| 17698397 | ASSAY FOR DETERMINING TARGET ENGAGEMENT IN REAL-TIME IN LIVING SYSTEMS | March 2022 | February 2026 | Abandon | 47 | 4 | 1 | No | No |
| 17638822 | CRM197 PROTEIN EXPRESSION METHOD | February 2022 | October 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17638596 | BIOSYNTHETIC METHODS FOR THE PRODUCTION OF L-4-CHLOROKYNURENINE | February 2022 | January 2026 | Abandon | 47 | 4 | 1 | No | No |
| 17672542 | NOVEL P450-BM3 VARIANTS WITH IMPROVED ACTIVITY | February 2022 | June 2023 | Allow | 16 | 1 | 1 | Yes | No |
| 17667379 | ENGINEERED POLYMERASES FOR IMPROVED SEQUENCING BY BINDING | February 2022 | September 2023 | Allow | 19 | 2 | 1 | No | No |
| 17586772 | ENZYMATIC CIRCUITS FOR MOLECULAR SENSORS | January 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17621052 | A Chemo-Enzymatic Process for the Preparation of Homopropargylic Alcohol | December 2021 | December 2024 | Allow | 36 | 1 | 1 | No | No |
| 17620654 | RARE EARTH ELEMENT (REE)-BINDING PROTEINS | December 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17554128 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | December 2021 | October 2025 | Abandon | 46 | 5 | 1 | Yes | No |
| 17547429 | METHODS AND COMPOSITIONS FOR IMPROVED PRODUCTION OF AN ANTIGEN FOR USE IN AN S. AUREUS VACCINE | December 2021 | December 2023 | Abandon | 24 | 0 | 1 | No | No |
| 17596281 | CA2 COMPOSITIONS AND METHODS FOR TUNABLE REGULATION | December 2021 | March 2026 | Abandon | 51 | 2 | 1 | No | No |
| 17541565 | GERANYLGERANYL PYROPHOSPHATE SYNTHASES | December 2021 | May 2023 | Allow | 18 | 1 | 1 | Yes | No |
| 17456166 | Processes and Systems for Catalytic Manufacture of Wax Ester Derivatives | November 2021 | January 2026 | Allow | 49 | 2 | 1 | Yes | No |
| 17527429 | MODIFIED STRAINS FOR THE PRODUCTION OF RECOMBINANT SILK | November 2021 | February 2026 | Allow | 51 | 1 | 1 | Yes | No |
| 17520849 | ENZYMES AND METHODS FOR PREVENTING AND TREATING PYRETHROID EXPOSURE IN ANIMALS | November 2021 | November 2023 | Abandon | 24 | 2 | 1 | Yes | No |
| 17520714 | ENTEROBACTER CHENGDUENSIS FOR PRODUCING NICOTINAMIDE MONONUCLEOTIDE AND APPLICATION THEREOF | November 2021 | October 2022 | Abandon | 11 | 1 | 1 | No | No |
| 17453306 | MODIFIED CHLORAMPHENICOL ACETYLTRANSFERASE AND BIOSYNTHESIS METHOD OF MAKING ESTERS USING SAME | November 2021 | December 2024 | Abandon | 37 | 4 | 1 | Yes | No |
| 17506676 | Preparation and Application of Soluble Tim-3 Recombinant Protein and Mutant Protein Thereof | October 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17505060 | METHOD FOR DEGRADING BENZO(A)PYRENE WITH A HALOPHILIC BACTERIUM STRAIN OF STAPHYLOCOCCUS HAEMOLITICUS | October 2021 | July 2025 | Abandon | 45 | 2 | 1 | Yes | Yes |
| 17604623 | A NITRILASE MUTANT AND APPLICATION THEREOF IN THE SYNTHESIS OF AN ANTI-EPILEPTIC DRUG INTERMEDIATE | October 2021 | January 2024 | Allow | 27 | 2 | 1 | Yes | No |
| 17491845 | Lysin Agent and Method of Use for Diagnostic Testing | October 2021 | November 2023 | Abandon | 26 | 2 | 1 | No | No |
| 17600345 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS | September 2021 | March 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17599696 | METHOD OF PREPARING TOXIN | September 2021 | October 2024 | Allow | 36 | 4 | 0 | No | No |
| 17442459 | NOVEL BIFIDOBACTERIUM GENUS BACTERIUM HAVING HIGH CAPACITY TO UTILIZE POLYSACCHARIDES OF DIETARY ORIGIN | September 2021 | March 2025 | Allow | 42 | 3 | 0 | Yes | No |
| 17462849 | HYDROGEL COMPOSITION, MANUFACTURING METHOD THEREOF AND ENZYMATICALLY FORMED HYDROGEL COMPOSITION | August 2021 | October 2024 | Abandon | 38 | 2 | 1 | No | No |
| 17407892 | SESQUITERPENE SYNTHASES FOR PRODUCTION OF DRIMENOL AND MIXTURES THEREOF | August 2021 | April 2023 | Allow | 20 | 2 | 0 | Yes | No |
| 17405012 | RECOMBINANT PROTEINS HAVING ENZYME ACTIVITY AGAINST MICROCYSTIN AND METHODS OF WATER REMEDIATION | August 2021 | June 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17427171 | Method of Making 2-Oxygenated Decalins From Isoprenoids Using a Squalene-Hopene Cyclase | July 2021 | January 2024 | Allow | 30 | 1 | 1 | Yes | No |
| 17386106 | AN EXPRESSION VECTOR ENCODING A PAENIBACILLUS POLYMXA NEUTRAL PROTEASE | July 2021 | August 2022 | Allow | 13 | 2 | 0 | No | No |
| 17415856 | SINGLE STEP BIOCATALYTIC AMIDATION | June 2021 | October 2024 | Allow | 40 | 4 | 1 | No | No |
| 17350909 | TREATMENT OF SANFILIPPO SYNDROME TYPE B | June 2021 | February 2025 | Abandon | 44 | 3 | 2 | No | No |
| 17348363 | YEAST CELLS HAVING REDUCTIVE TCA PATHWAY FROM PYRUVATE TO SUCCINATE AND OVEREXPRESSING AN EXOGENOUS NAD(P+) TRANSHYDROGENASE ENZYME | June 2021 | March 2023 | Allow | 21 | 1 | 1 | Yes | No |
| 17337613 | Lipolytic Enzyme for Use in Baking | June 2021 | September 2022 | Allow | 15 | 0 | 0 | Yes | No |
| 17297606 | REAGENTS AND METHODS FOR CONTROLLING PROTEIN FUNCTION AND INTERACTION | May 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17332459 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE | May 2021 | September 2024 | Allow | 40 | 7 | 1 | Yes | No |
| 17327319 | ENHANCEMENT OF KINASE TARGET ENGAGEMENT | May 2021 | October 2024 | Abandon | 40 | 2 | 1 | No | No |
| 17317812 | BREVIBACILLUS AGRI, PREPARATION THEREOF, METHOD FOR PREPARING SURFACTANT AND USE THEREOF | May 2021 | November 2023 | Allow | 30 | 2 | 1 | No | No |
| 17289946 | GENETICALLY ENCODED FLUORESCENT INDICATORS UNDER OPTOGENETIC CONTROL AND USES THEREOF | April 2021 | December 2025 | Allow | 56 | 3 | 1 | Yes | No |
| 17239325 | RECOMBINANT COMPONENTS AND COMPOSITIONS FOR USE IN FOOD PRODUCTS | April 2021 | January 2024 | Allow | 33 | 4 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner STEADMAN, DAVID J.
With a 12.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 11.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner STEADMAN, DAVID J works in Art Unit 1656 and has examined 1,210 patent applications in our dataset. With an allowance rate of 49.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner STEADMAN, DAVID J's allowance rate of 49.6% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by STEADMAN, DAVID J receive 2.25 office actions before reaching final disposition. This places the examiner in the 63% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by STEADMAN, DAVID J is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +36.6% benefit to allowance rate for applications examined by STEADMAN, DAVID J. This interview benefit is in the 84% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 16.5% of applications are subsequently allowed. This success rate is in the 13% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 29.1% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 40.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 36% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 63.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 69.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 75.5% are granted (fully or in part). This grant rate is in the 81% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.
Examiner's Amendments: This examiner makes examiner's amendments in 6.0% of allowed cases (in the 88% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 8.0% of allowed cases (in the 86% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.